Evidence-based guidelines for managing patients with primary ER+ HER2− breast cancer deferred from s...
Evidence-based guidelines for managing patients with primary ER+ HER2− breast cancer deferred from surgery due to the COVID-19 pandemic
About this item
Full title
Author / Creator
Dowsett, Mitch , Ellis, Matthew J. , Dixon, J. Michael , Gluz, Oleg , Robertson, John , Kates, Ronald , Suman, Vera J. , Turnbull, Arran K. , Nitz, Ulrike , Christgen, Matthias , Kreipe, Hans , Kuemmel, Sherko , Bliss, Judith M. , Barry, Peter , Johnston, Stephen R. , Jacobs, Samuel A. , Ma, Cynthia X. , Smith, Ian E. and Harbeck, Nadia
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
Many patients with ER+ HER2− primary breast cancer are being deferred from surgery to neoadjuvant endocrine therapy (NeoET) during the COVID-19 pandemic. We have collated data from multiple international trials of presurgical endocrine therapy in order to provide guidance on the identification of patients who may have insufficiently endocrine-sensi...
Alternative Titles
Full title
Evidence-based guidelines for managing patients with primary ER+ HER2− breast cancer deferred from surgery due to the COVID-19 pandemic
Authors, Artists and Contributors
Author / Creator
Ellis, Matthew J.
Dixon, J. Michael
Gluz, Oleg
Robertson, John
Kates, Ronald
Suman, Vera J.
Turnbull, Arran K.
Nitz, Ulrike
Christgen, Matthias
Kreipe, Hans
Kuemmel, Sherko
Bliss, Judith M.
Barry, Peter
Johnston, Stephen R.
Jacobs, Samuel A.
Ma, Cynthia X.
Smith, Ian E.
Harbeck, Nadia
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7280290
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7280290
Other Identifiers
ISSN
2374-4677
E-ISSN
2374-4677
DOI
10.1038/s41523-020-0168-9
